MedPlus top gainer

Shares of MedPlus Health Services rose sharply in early trade, hitting an intraday high of Rs. 880.45. The stock opened at Rs. 789.80 against a previous close of Rs. 762.90, and traded with a VWAP of Rs. 845.53 (day’s range: Rs. 787.75–880.45). Market capitalisation stood at Rs. 10,031.55 crore. The move comes despite ongoing suspension actions at select outlets, as investors weighed fresh stay orders and stronger quarterly results.

In an exchange filing, the company said it has received a stay order against the May 22, 2024 suspension of a store at Patidar Complex, Vikhroli (Maharashtra). Its subsidiary Optival Health Solutions, received two stay orders from authorities in Nagpur and Amravati (Maharashtra) against a 21-day drug-license suspension at a store in Shantinagar, Nagpur, while one store in Andhra Pradesh remains under a suspension order. Management indicated such actions are localised compliance matters and have been seen earlier (including in July 2025) without much of a material impact on operations.

The stock also reacted to Q2 FY26 results: consolidated net profit rose 43.3% YoY to Rs. 55.50 crore, with revenue up 6.5% to Rs. 1,680  crore. EBITDA increased 22% to Rs. 166 crore, and EBITDA margin improved to 9.9% (vs. 8.6% in Q2 FY25). Segmentally, retail revenue grew 6% to Rs. 1,646 crore, while diagnostic services rose 17% to Rs. 33 crore.

Traders pointed to a relief rally driven by the stay orders and margin expansion in Q2, with today’s strength reflecting bargain buying and short covering after recent volatility. The market will watch for any further regulatory clarifications and the sustainability of margin gains through the second half.